Expand CNTB Menu
CNTB MENU

CNTB Stock Posts


CNTB stock declines -38.0% in premarket,

Premarket Decliner

CNTB Connect Biopharma Hldgs1.73-0.31-15.4%

Premarket:1.07-0.65 (-38.0%)

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

Globe NewswireTue, 15-Sep 7:00 AM
Unusual Option Volume

CNTB Connect Biopharma Hldgs1.85-0.08 (-4.2%)

Connect Biopharma Hldgs trades 3,624 contracts. The company has the following event: H.C. Wainwright 28th Annual Global Investment Conference on Sep 15, 2026. News: Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
View Details...
Unusual Option Volume

CNTB Connect Biopharma Hldgs2.28-0.48 (-17.4%)

Connect Biopharma Hldgs trades 2,795 contracts.
View Details...
Unusual Option Volume

CNTB Connect Biopharma Hldgs1.99-0.10 (-4.8%)

Connect Biopharma Hldgs trades 2,370 contracts. The highest volume is in the 18-Sep-26 5 calls, which is 151.3% above the current price.
View Details...
Upcoming Earnings

CNTB Connect Biopharma Hldgs1.410.00 (0.0%)

Connect Biopharma Hldgs will report earnings after the market closes. View Calendar The market is expecting a ±10.1% move after earnings are reported. View Expected Move (Conf Call: Sep 13 4:30 PM)
CNTB stock declines -11.1% in premarket,

Premarket Decliner

CNTB Connect Biopharma Hldgs5.70-0.22-3.7%

Premarket:5.07-0.63 (-11.1%)

Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Globe NewswireWed, 5-Jan 7:00 AM
Load Earlier Posts
Market Data Delayed 15 Minutes